Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b2 + BNT162b2 OMI
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**BNT162b2 + BNT162b2 OMI** is an investigational bivalent mRNA COVID-19 vaccine developed by BioNTech and Pfizer. The 60 µg booster formulation evaluated in Substudy F of the Phase 3 C4591031 master protocol contains 30 µg of original-strain BNT162b2 mRNA and 30 µg of Omicron BA.1-adapted BNT162b2 OMI mRNA. Both mRNAs are delivered in lipid nanoparticles and encode SARS-CoV-2 spike antigens, inducing neutralizing antibodies and cellular immune responses intended to broaden protection against ancestral SARS-CoV-2 and the Omicron BA.1 variant. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04955626))
- Other names
- BNT162b2/BNT162b2 OMIbivalent BA.1-adapted BNT162b2bivalent BNT162b2 + BNT162b2 OMIbivalent Omicron BA.1-adapted BNT162b2
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on BNT162b2 + BNT162b2 OMI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b2 + BNT162b2 OMI.